Skip to main content

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Project description

A pioneering vaccine for diarrhoea may accomplish what predecessors could not

Diarrhoea is typically a non-threatening nuisance in western civilisations but it is a killer in developing countries, particularly for children under five years of age. In cases where children do survive, malnourishment due to poverty is augmented by dehydration and severe undernutrition as a result of infection. This can have long-term effects on physical and cognitive development. SHIGETECVAX is developing a novel oral vaccine against two closely related bacteria that are leading causes of diarrhoea. Based on antigens not targeted in previous vaccines, it is much safer, enabling higher doses. Potentially more effective against both pathogens, this vaccine could save millions of lives.

Call for proposal

H2020-SC1-2018-Two-Stage-RTD
See other projects for this call

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV
Address
Vossstrasse 2 Geb 4040
69115 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 359 755

Participants (4)

EVELIQURE BIOTECHNOLOGIES GMBH
Austria
EU contribution
€ 5 024 401,62
Address
Karl-farkas-gasse 22
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GOETEBORGS UNIVERSITET
Sweden
EU contribution
€ 749 842,50
Address
Vasaparken
405 30 Goeteborg
Activity type
Higher or Secondary Education Establishments
INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH
Bangladesh
EU contribution
€ 1 924 713,27
Address
Shaheed Tajuddin Ahmed Sharani 68
1212 Dhaka
Activity type
Research Organisations
PATH
United States
EU contribution
€ 545 277,54
Address
2201 Westlake Avenue, Suite 200
98121 2767 Seattle
Activity type
Research Organisations